Abdo E, Ajib I, El Mounzer J, Husseini M, Kalaoun G, Matta T
Inflamm Res. 2025; 74(1):41.
PMID: 39960501
DOI: 10.1007/s00011-025-02008-5.
Wunderle V, Wilhelm T, Boukeileh S, Gossen J, Margreiter M, Sakurov R
Eur J Immunol. 2024; 55(2):e202451348.
PMID: 39676406
PMC: 11830387.
DOI: 10.1002/eji.202451348.
Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P
Med Drug Discov. 2024; 23.
PMID: 39281823
PMC: 11393807.
DOI: 10.1016/j.medidd.2024.100195.
du Plessis J, Deroubaix A, Omar A, Penny C
Curr Issues Mol Biol. 2024; 46(8):8600-8610.
PMID: 39194723
PMC: 11352951.
DOI: 10.3390/cimb46080506.
Mehra A, Sangwan R
Anticancer Agents Med Chem. 2024; 25(1):2-23.
PMID: 39192641
DOI: 10.2174/0118715206318833240819031953.
Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.
Joshi D, Sharma A, Prasad S, Singh K, Kumar M, Sherawat K
Discov Oncol. 2024; 15(1):342.
PMID: 39127974
PMC: 11317456.
DOI: 10.1007/s12672-024-01195-7.
A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures.
Herrington N, Li Y, Stein D, Pandey G, Schlessinger A
PLoS Comput Biol. 2024; 20(7):e1012302.
PMID: 39046952
PMC: 11268620.
DOI: 10.1371/journal.pcbi.1012302.
Overcoming Secondary Mutations of Type II Kinase Inhibitors.
Wang X, DeFilippis R, Yan W, Shah N, Li H
J Med Chem. 2024; 67(12):9776-9788.
PMID: 38837951
PMC: 11586107.
DOI: 10.1021/acs.jmedchem.3c01629.
Protein characteristics substantially influence the propensity of activity cliffs among kinase inhibitors.
Daoud S, Taha M
Sci Rep. 2024; 14(1):9058.
PMID: 38643174
PMC: 11032345.
DOI: 10.1038/s41598-024-59501-w.
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
Veiga R, de Azevedo A, de Oliveira J, Gradia D
J Mol Med (Berl). 2024; 102(4):479-493.
PMID: 38393661
DOI: 10.1007/s00109-024-02431-x.
Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies.
Fouad M, Osman A, Abdelhamid N, Rashad M, Nabawy A, El Kerdawy A
BMC Chem. 2024; 18(1):29.
PMID: 38347617
PMC: 10863211.
DOI: 10.1186/s13065-024-01130-5.
How many kinases are druggable? A review of our current understanding.
Anderson B, Rosston P, Ong H, Hossain M, Davis-Gilbert Z, Drewry D
Biochem J. 2023; 480(16):1331-1363.
PMID: 37642371
PMC: 10586788.
DOI: 10.1042/BCJ20220217.
In Silico Discovery of 5'-Modified 7-Deoxy-7-ethynyl-4'-thioadenosine as a HASPIN Inhibitor and Its Synergistic Anticancer Effect with the PLK1 Inhibitor.
Kwon E, Mashelkar K, Seo J, Shin Y, Sung K, Jang S
ACS Cent Sci. 2023; 9(6):1140-1149.
PMID: 37396870
PMC: 10311661.
DOI: 10.1021/acscentsci.3c00332.
Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors.
Kim D, Orr M, Kwong A, Deibler K, Munshi H, Bridges C
ACS Med Chem Lett. 2023; 14(5):606-613.
PMID: 37197477
PMC: 10184151.
DOI: 10.1021/acsmedchemlett.3c00029.
Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines.
Nojima Y, Aoki M, Re S, Hirano H, Abe Y, Narumi R
Comput Struct Biotechnol J. 2023; 21:2172-2187.
PMID: 37013003
PMC: 10066531.
DOI: 10.1016/j.csbj.2023.03.006.
Design, synthesis and evaluation of a series of potential prodrugs of a Bruton's tyrosine kinase (BTK) inhibitor.
Xiao Z, Liao M, Huang X, Wang Y, Lan X, Wang X
Front Pharmacol. 2023; 14:1162216.
PMID: 36969836
PMC: 10031131.
DOI: 10.3389/fphar.2023.1162216.
Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach.
Bogari H, Elhady S, Darwish K, Refaey M, Mohamed R, Abdelhameed R
Metabolites. 2023; 13(2).
PMID: 36837781
PMC: 9964656.
DOI: 10.3390/metabo13020162.
Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update.
Naik R, Shakya A
Front Pharmacol. 2023; 13:1064472.
PMID: 36699049
PMC: 9868582.
DOI: 10.3389/fphar.2022.1064472.
Mechanistic Insights into Biological Activities of Polyphenolic Compounds from Rosemary Obtained by Inverse Molecular Docking.
Lesnik S, Bren U
Foods. 2022; 11(1).
PMID: 35010191
PMC: 8750736.
DOI: 10.3390/foods11010067.
Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S, George S, von Mehren M, Heinrich M
Front Oncol. 2021; 11:672500.
PMID: 34322383
PMC: 8313277.
DOI: 10.3389/fonc.2021.672500.